Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWE-NEO neoadjuvant immunotherapy trial in resectable stage III melanoma
2024-519593-39-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Opdivo monotherapy with Yervoy + Opdivo combination (2 arms). Primary endpoint: Event-free survival. Planned start Jun 2025; status: authorised.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-519593-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519593-39-00.